Expanded global capacity addresses growing demand for cell and gene therapy
• A disposal aligned with Novasep’s core strategy
• An opportunity for Novasep’s chromatography equipment division to accelerate its growth by joining an established leader in the sector
An ambitious goal to develop the skills necessary for health independence
Novasep announces a €6.5 million investment to upgrade an API manufacturing workshop at its Chasse-sur-Rhône site (69 - France)
This agreement covers the development and manufacturing of an Adeno-Associated Virus (AAV) based gene therapy drug candidate for the treatment of neurodegenerative diseases
• Agreement covers the development and manufacturing of AAV vectors, a key step for Sensorion’s gene therapy programs
• Agreement secures drug product development and manufacturing capacity for the Company’s Otoferlin program
• Gene therapy could revolutionize the treatment of genetic inner ear disorders
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Frontier Biotechnologies Inc. (“Frontier Biotech”) chooses Novasep Prochrom® HPLC chromatography columns and skids for its Nanjing (China) site.
Novasep will produce the active substance of the vaccine in its Belgian facilities
This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)